AVADEL PHARMACEUTICALS PLC 4

Jerad G. Seurer, General Counsel & Corporate Secretary of Avadel Pharmaceuticals, had 23,496 ordinary shares cashed out at $21.00 per share and 461,500 option shares canceled for cash and CVRs in connection with Alkermes’ acquisition of Avadel on 2026-02-12.

On February 12, 2026, Jerad G. Seurer, General Counsel & Corporate Secretary of Avadel Pharmaceuticals plc, disposed of all of his equity interests in connection with the cash acquisition of Avadel by Alkermes plc. Each of his 23,496 ordinary shares (including previously restricted stock) was converted into $21.00 in cash plus a contingent value right (CVR) worth a potential additional $1.50 per share, resulting in cash consideration of approximately $493,416 and potential CVR value of about $35,244. Concurrently, all of his outstanding stock options with exercise prices ranging from $4.69 to $13.57 and covering an aggregate of 461,500 underlying ordinary shares (25,000 + 30,000 + 80,000 + 47,500 + 100,000 + 125,000 + 84,000) were canceled and exchanged for cash equal to the intrinsic value based on the $21.00 deal price plus one CVR per option share, yielding estimated intrinsic value of roughly $7.6 million (excluding tax/withholding) plus associated CVRs. Following these merger-related, non‑open‑market transactions, Seurer no longer holds Avadel ordinary shares or options as a standalone public security, having instead received cash and CVRs pursuant to the transaction agreement.

Filing Facts

CIK

1012477

Ticker

AVDL

Form

4

Source Type

sec

Accession

0001104659-26-014447

Alert Tier

6